GKB Ophthalmics
BSE: GKB · Medical Equipment & Supplies
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock GKB Ophthalmics's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
GKB Ophthalmics Ltd specialises in the manufacturing and distribution of ophthalmic lenses, including both glass and plastic variants. Its product portfolio encompasses single-vision glass, single-vision plastic, bifocal plastic, and photochromic plastic lenses.
Business Model
The company generates revenue through the manufacturing and sale of semi-finished ophthalmic lenses to the optical industry. It leverages its production capabilities to supply various lens types to meet market demand for vision correction products.
- Incorporation Year:1981
Growth Outlook
Growth is primarily driven by the increasing demand for vision correction products and the expansion of the global ophthalmic lens market. The company focuses on maintaining its manufacturing output to cater to evolving consumer preferences in lens materials.
Key Risks
- Raw Material Price Volatility. Fluctuations in the cost of glass and plastic raw materials can significantly impact the company's manufacturing margins.
- Technological Obsolescence. Rapid advancements in lens technology and materials may render existing manufacturing processes or product lines less competitive.
- Regulatory Compliance. The company must adhere to stringent international and domestic quality standards for medical devices, which may involve high compliance costs.
- Competitive Pressure. The ophthalmic lens market is highly competitive, with numerous global and local players exerting pressure on pricing and market share.
Start your research today
Unlock AI insights, financials, peers and live data on GKB Ophthalmics and 5,000+ companies — free.
Key Metrics
REVENUE
₹149 Cr
TTM · consolidated
NET PROFIT
₹4 Cr
TTM · consolidated
EPS
₹6.45
TTM · consolidated
RETURN ON EQUITY
8.3%
TTM · consolidated
P/E
9.1x
Q4 FY26 · consolidated
EV/EBITDA
3.3x
Q4 FY26 · consolidated
EBITDA MARGIN
7.8%
TTM · consolidated
NET PROFIT MARGIN
3.8%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Medical Equipment & Supplies
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
GKB OphthalmicsGKB | ₹32 Cr | 9.69 | 3.47 | 36.8% | 7.8% | 8.3% | 11.1% | -19.3% |
Tarsons ProductsTARSONS | ₹1,768 Cr | 158.97 | 14.57 | 10.6% | 33.1% | 1.8% | 4.5% | +6.6% |
Laxmi DentalLAXMIDENTL | ₹1,098 Cr | 35.30 | 19.82 | — | 19.2% | 13.7% | 13.3% | -41.5% |
Vasa Denticity LimitedDENTALKART | ₹709 Cr | — | — | — | 4.0% | — | — | -34.1% |
Hemant Surgical Industries LimitedHSIL | ₹539 Cr | — | — | — | 10.0% | — | — | +27.0% |
Prevest DenproPREVEST | ₹464 Cr | — | — | — | 36.0% | — | — | -31.5% |
As of Q4 FY26
Financials
GKB Ophthalmics
BSE: GKB · Medical Equipment & Supplies
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock GKB Ophthalmics's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
GKB Ophthalmics Ltd specialises in the manufacturing and distribution of ophthalmic lenses, including both glass and plastic variants. Its product portfolio encompasses single-vision glass, single-vision plastic, bifocal plastic, and photochromic plastic lenses.
Business Model
The company generates revenue through the manufacturing and sale of semi-finished ophthalmic lenses to the optical industry. It leverages its production capabilities to supply various lens types to meet market demand for vision correction products.
- Incorporation Year:1981
Growth Outlook
Growth is primarily driven by the increasing demand for vision correction products and the expansion of the global ophthalmic lens market. The company focuses on maintaining its manufacturing output to cater to evolving consumer preferences in lens materials.
Key Risks
- Raw Material Price Volatility. Fluctuations in the cost of glass and plastic raw materials can significantly impact the company's manufacturing margins.
- Technological Obsolescence. Rapid advancements in lens technology and materials may render existing manufacturing processes or product lines less competitive.
- Regulatory Compliance. The company must adhere to stringent international and domestic quality standards for medical devices, which may involve high compliance costs.
- Competitive Pressure. The ophthalmic lens market is highly competitive, with numerous global and local players exerting pressure on pricing and market share.
Start your research today
Unlock AI insights, financials, peers and live data on GKB Ophthalmics and 5,000+ companies — free.
Key Metrics
REVENUE
₹149 Cr
TTM · consolidated
NET PROFIT
₹4 Cr
TTM · consolidated
EPS
₹6.45
TTM · consolidated
RETURN ON EQUITY
8.3%
TTM · consolidated
P/E
9.1x
Q4 FY26 · consolidated
EV/EBITDA
3.3x
Q4 FY26 · consolidated
EBITDA MARGIN
7.8%
TTM · consolidated
NET PROFIT MARGIN
3.8%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Medical Equipment & Supplies
As of Q4 FY26